Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSC prophylaxis for GVHD after haploidentical stem cell transplantation
ChiCTR1900022292Phase 4Recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Apr 2019
- Countries
- 1
01
Overview
Phase 4, open-label trial of umbilical cord-derived mesenchymal stromal cells in graft-versus-host disease (GVHD) (2 arms), sponsored by Xinqiao Hospital. Primary endpoint: Incidence of chronic graft-versus-host disease. Started Apr 2019; status: recruiting.
02
Drugs
umbilical cord-derived mesenchymal stromal cells
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on ChiCTR1900022292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022292.